Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | CGEM Cullinan Therapeutics, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $15.44 -8.5% | $15.23 -2.2% |
| StockIQ Score | 40D Weak Risk: High | 36F Weak Risk: Medium |
| Technical | 16F | 13F |
| Fundamental | 46D+ | 35F |
| Growth | 38F | 50C- |
| Fair Value | 50C- | 38F |
| News | 74B | 50C- |
| Quality | — | 50C- |
| Risk | 40D | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Cullinan Therapeutics (CGEM) outperforms Ascentage Pharma (AAPG) in investor confidence and technical strength, with scores of 57 vs. 37 and 68 vs. 18, respectively. However, AAPG leads in growth potential, scoring 50 compared to CGEM’s 38. Both have similar valuation scores, but CGEM’s moderate rating contrasts with AAPG’s weak classification.
